NCT04931979View on ClinicalTrials.gov

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

April 1, 2026

Conditions
Urologic CancerBiochemical Recurrence of Malignant Neoplasm of Prostate
Interventions
DRUG

Pembrolizumab Injection [Keytruda]

Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)

RADIATION

Salvage Radiation Therapy (SRT)

SRT according to standard of care (SRT with at least 66 Gy)

Trial Locations (1)

79106

RECRUITING

Clinic of Urology, Medical Center - University of Freiburg, Freiburg im Breisgau

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Prof. Dr. med. Christian Gratzke

OTHER